Early-stage diagnoses for adults aged 45 to 49 jumped, thanks to more screening.
Find insight on Sigma Healthcare, Hartalega, Roche and more in the latest Market Talks covering Health Care.
Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.
Without proper monitoring, even the healthy and active ‘younger old’ can suffer a bad spill, experts say.
The tang of chlorine and the feel of water make the stresses and tragedies of life more manageable.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Find insight on Moderna, European pharmaceutical companies and more in the latest Market Talks covering Health Care.
To treat PTSD, the Department of Veterans Affairs put hundreds of thousands of patients on multiple streams of powerful drugs that put them at risk of suicide.
Find insight on Novo Nordisk, GSK, Sanofi and more in the latest Market Talks covering Health Care.
The healthcare giant’s results underscore a split among insurers between those that are struggling and those that are beginning to revive.
The company’s first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.
Find insight on AstraZeneca, Philips, Raffles Medical Group and more in the latest Market Talks covering the Health Care sector.
The bankruptcies of Steward Health Care and Prospect Medical have left communities with gaps in healthcare and government budgets.
The brain disease commonly known as CTE, caused by repeated head trauma, has prompted a long reckoning at all levels of football. The shooter at NFL headquarters believed he was suffering from it.
Returning CEO Stephen Hemsley is lowering expectations, but perhaps not enough.
Ultrapotent synthetics, mostly from China, are easy to smuggle and mix into heroin, recreational drugs and gray-market pharmaceuticals.
The National Institutes of Health can’t award grants to outside researchers under a new White House restriction.
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S. regulators ordering an end to the practice.
Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.
Find insight on AstraZeneca, Philips, EssilorLuxottica and more in the latest Market Talks covering Health Care.
Coca-Cola says it is launching a new line of soda sweetened with cane sugar.
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.
Trump Administration aims to soften the blow by negotiating with insurers.
Find insight on the tariff deal between the U.S. and EU and more in the latest Market Talks covering Health Care.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.